TARA Share Price Performance
US$5.61
3.99 (246.30%)
Price US$5.61
Share PriceUS$5.61
We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth
Jul 10
Protara Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
TARA Community Narratives
There are no narratives available yet.
Recent TARA News & Updates
Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025
Jun 14Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
Mar 28We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely
Mar 07Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Dec 10Protara Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.32
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Protara Therapeutics, Inc. Competitors
Snowflake Analysis
About TARA
- Founded
- n/a
- Employees
- 31
- CEO
- WebsiteView website
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: 0.3%
- 3 Months: 8.5%
- 1 Year: 17.3%
- Year to Date: 15.0%
In the last week, the market has been flat. As for the longer term, the market has risen 17% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›